(Q37965555)

26 August 2017

title

Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity (English)

1 reference

26 August 2017

1 reference

Juergen Hess

1

1 reference

26 August 2017

Peter Ruf

series ordinal

2

1 reference

26 August 2017

Horst Lindhofer

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

73-85

1 reference

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Two new trifunctional antibodies for the therapy of human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

T cell growth factor receptors. Quantitation, specificity, and biological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Complement function in mAb-mediated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Structural and functional characterization of the trifunctional antibody catumaxomab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Th1-Th2: reliable paradigm or dangerous dogma?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Cutting edge: migration to nonlymphoid tissues results in functional conversion of central to effector memory CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunotherapy of malignant ascites with trifunctional antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Catumaxomab: clinical development and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Malignant ascites: a 2-year review from a teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Antibody humanization: a case of the 'Emperor's new clothes'?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunoglobulin G: functional sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Tolerance to rat monoclonal antibodies. Implications for serotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Management of loss of response to anti-TNF drugs: Change the dose or change the drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.138

21 January 2018

Identifiers

DOI

10.2217/FON.11.138

1 reference

26 August 2017

1 reference